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Abstract
Background: Natural products represent an important source for agents of cancer prevention and cancer treatment. More
than 60% of conventional anticancer drugs are derived from natural sources, particularly from plant-derived materials. In
this study, 2a,3 a,1 9 b,2 3 b-tetrahydroxyurs-12-en-28-oic acid (THA), a novel triterpenoid from the leaves of Sinojackia
sarcocarpa, was isolated, and its anticancer activity was investigated both in vitro and in vivo.
Principal Findings: THA possessed potent tumor selected toxicity in vitro. It exhibited significantly higher cytotoxicity to the
cancer cell lines A2780 and HepG2 than to IOSE144 and QSG7701, two noncancerous cell lines derived from ovary
epithelium and liver, respectively. Moreover, THA showed a dose-dependent inhibitory effect on A2780 ovary tumor growth
in vivo in nude mice. THA induced a dose-dependent apoptosis and G2/M cell cycle arrest in A2780 and HepG2 cells. The
THA-induced cell cycle arrest was accompanied by a downregulation of Cdc2. The apoptosis induced by THA was evident
by induction of DNA fragmentation, release of cytoplasmic Cytochrome c from mitochondria, activation of caspases,
downregulation of Bcl-2 and upregulation of Bax.
Conclusion: The primary data indicated that THA exhibit a high toxicity toward two cancer cells than their respective non-
cancerous counterparts and has a significant anticancer activity both in vitro and in vivo. Thus, THA and/or its derivatives
may have great potential in the prevention and treatment of human ovary tumors and other malignancies.
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Introduction
Natural products represent a rich reservoir for anticancer
compounds [1,2]. Over sixty percent of currently used anticancer
drugs are derived from natural sources such as plants, marine
organisms and microorganisms [3,4]. In particular, higher plants
have provided many effective, clinically useful anticancer drugs.
For examples, the vinca bisindole alkaloids, the epipodophyllo-
toxin analogs, the taxanes, and the camptothecins, are all effective
plant-derived anticancer drugs [5,6].
In the past decades, there is growing interest in another group of
natural compound: the triterpenoids. Triterpenoids are structur-
ally diverse organic compounds of more than 20,000 naturally
occurring variants that share a basic triterpenoid moiety [7,8].
These compounds are ubiquitously distributed throughout the
plant kingdom and have many biological activities. For examples,
several triterpenoids, including saponin, oleanolic acid, betulinic
acid, celastrol, pristimerin, lupeol, and avicins have been reported
to possess anti-inflammatory, hepato-protective, or antitumor
properties [9,10]. In particular, ursolic acid has been shown to
constitute a main active component in a number of oriental and
traditional medicine herbs with a variety of biological activities
including induction of differentiation, anti-proliferation, and
antitumor activities [11–13]. Mechanistically, triterpenoids have
been implicated in a wide range of biological pathways or
processes including nuclear factor-kappaB signalling, apoptosis,
transcription, angiogenesis, and tumor metastasis [14–16]. Thus,
these compounds are potential candidates for anticancer agents.
Recently, a number of compounds with anti-proliferative and/
or antitumor activities have been isolated from plants of the
Styracaceae family, suggesting that this family of plants may be a
new source for compounds with anticancer activities [17–23].
Sinojackia sarcocarpa is a member of the Styracaceae family [24]. It
consists of primarily deciduous arbor trees that are distributed in
the subtropical zone of the Eastern and Southern China, and was
once at the brink of extinction. Intriguing, this endangered status
has prompted a great effort in the development and optimization
of propagation and cultivation technologies for these plants. As
a result, it represents an attractive source for raw materials
of its family. Here, we report the identification of 2a,3 a,1 9 b,
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molecule from Sinojackia sarcocarpa. More importantly, we have
shown that THA exhibited a significantly higher cytotoxic effect
towards an ovarian cancer cell line and a liver cancer cell line than
their respective noncancerous counterparts. The compound also
elicited a G2 arrest and a significant apoptotic response. It was
well tolerated and exhibited significant antitumor activity in nude
mice.
Methods
Reagents
Tissue culture plasticware was purchased from BD Biosciences
(USA). Column chromatography (silica gel 60), HPLC grade
acetonitrile and dimethylsulphoxide (DMSO) were from Merck
(Germany). Propidium iodide (PI) was product of Sigma (USA).
The broad-spectrum caspase inhibitor z-VAD-fmk, anti-human
p21 (C-19), Bcl-2 (100), Bax (N-20), procaspase-3 (N-19),
procaspase-8 (8CSP03), procaspase-9 (4i31), Cyclin D1 (DCS-6),
Fas (B-10), Cdc2 (B-5), and PARP (H-250), together with all
secondary antibodies (anti-mouse, anti-goat and anti-rabbit
immunoglobulin G) were purchased from Santa Cruz Biotech-
nology, Inc. (USA). The anti-human Cytochrome c (4272) and
beta-actin (13E5) antibodies were from Cell Signaling Technology,
Inc. (USA). Anti-c-Myc (K422) was from Bioworld Technology,
Inc. (USA). Cell culture media, fetal bovine serum (FBS),
phosphate-buffered saline (PBS), sodium pyruvate, non-essential
amino acids, penicillin/streptomycin and other cell culture
supplies were obtained from Invitrogen (USA).
Cell culture
The Immortalized non-tumorigenic human ovarian surface
epithelial cells IOSE144 and human cancer cell lines HCT116,
HepG2, A2780, A549, PC3, MCF-7 and Eca109 were originally
obtained from the American Type Culture Collection (ATCC),
QSG7701 and other cell lines used in this study were from the Cell
Resources Centre of Shanghai Institute for Biological Sciences,
Chinese Academy of Sciences (China). Cells were grown in RPMI-
1640 or DMEM, with 10% FBS, 1% penicillin/streptomycin
solution (100 IU/ml penicillin, 100 mg/ml streptomycin) and
2 mM L-glutamine in a 5% CO2 atmosphere at 37uC.
THA preparation
The plant leaves of Sinojackia sarcocarpa were collected from the
forest in Sichuan, China. The isolation process of THA was
demonstrated in the Supporting information (Fig. S1). Briefly, the
dried leaves of Sinojackia sarcocarpa (10 kg) were extracted with
20 liter of 95% ethanol for 3 hour at room temperature and then
subjected to sonication. The material was concentrated with
vacuum to obtain a viscous extract of approximately 150 g. This
extract was suspended in water and extracted first with petroleum
ether and then EtOAc. This yielded approximately 20 grams of
EtOAc extract. The EtOAc extract (20 g) was further fractionated
by a silica gel column chromatography into 20 fractions. Finally,
fraction 6 (4.0 g) was subjected to HSCCC separation using a
standard hexane–ethyl acetate–methanol/water (10:5:3:1, v/v)
two-phase solvent procedure, yielding 460 mg final dried powder.
The structure of the major compound in this powder was
determined based on data from UV, IR, MS,
1H NMR, and
13C NMR spectra analyses.
Cell viability and clonogenic survival assays
The cell viability was determined by MTT assay. Briefly,
2,5610
4 cells per well were plated in triplicate in 96-well plates.
After 24 hr incubation at 37uC in 5% CO2, the cells were treated
with the THA at following concentrations: 2.5, 5, 10, 20, 40, 80
and 160 mg/ml, a DMSO treated group was kept as control. After
incubation for 72 hr, 10 ml of the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma, USA) stock solution
(5 mg/ml) was added into each well. The plates were incubated in
37uC, 5% CO2 for another 4 hr. The medium was carefully
removed from each well and 100 ml of DMSO was added. The
plates were gently agitated until the color reaction was uniform
and absorbance of the converted dye was measured at a
wavelength of 550 nm with Microplate Reader (BioRad Model
550). Microsoft-Excel 2000 was used for data analysis. The
percentage of viability was calculated as: % Viability=[OD of
treated cells/OD of control cells]6100. The IC20,I C 50,I C 80 were
defined as the THA concentrations that reduced the absorbance of
the treated wells by 20%, 50%, 80% as compared with the control
cells. To verify that THA does not react with the MTT assay
reagents, we also performed the MTT assay in the absence of cells.
The clonogenic survival assay was modified from the previous
report [25]. Briefly, cells were plated at a low density (500 viable
cells per well) in triplicate in 6-well culture plates without (control,
with DMSO) or in the presence of the THA. Seven days later, the
cells were fixed with 2% formaldehyde in PBS and stained with
hematoxylin, and colonies of more than 20 cells were scored.
Detection of apoptosis
The cells were plated in 6-well plate at a seeding density of
5610
5 cells/well and treated with different concentrations of THA
(0, 5, 10, 20, 40 mg/ml). After 48 hr of treatment, the cells were
Figure 1. Chemical structure and purity of THA. (A) The purity of
THA was determined by HPLC. (B) The chemical structure of THA was
identified as 2a,3 a,1 9 b,2 3 b-tetrahydroxyurs-12-en-28-oic acid.
doi:10.1371/journal.pone.0021130.g001
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trypsinized adherent cells were collected and stained with Annexin
V-FITC (Invitrogen, USA) following the manufacturer’s instruc-
tions. Samples were analyzed with a FACSAria
TM flow cytometer
(Becton Dickinson, USA) after incubation in the dark at room
temperature for 5 min. Cells positive for early apoptosis (Annexin
V-FITC stained only, see Q4 in figure) and for late apoptosis
(Annexin V-FITC and PI stained, see Q2 in figure) were
combined.
DNA fragmentation analysis
The appearance of DNA fragmentation was determined by
agarose gel electrophoresis [26]. The cells were treated as above
and washed with cold PBS. The cell pellets were lysed with 2%
SDS containing 10 mg/ml RNase A and incubated at 37uC for
2 hr. 5 M NaCl was added to a final concentration of 1 M, and
cells were scraped and stored at 4uC for 24 hr. The lysed cells were
centrifuged for 30 min at 12,000 rpm. DNA unassociated with
intact chromatin residing in the supernatant was extracted by
phenol-chloroform and precipitated with ethanol. DNA (10 mg)
was resolved by agarose gel electrophoresis in 16Tris-acetate-
EDTA for 1 hr on 1.5% agarose gel impregnated with ethidium
bromide.
Cell cycle measurements
5610
5 A2780 and HepG2 cells were seeded in 6-well plates and
allowed to adhere overnight and then the medium was removed
and replaced with fresh medium containing 0, 10, 20 and 40
mg/ml concentrations of the THA and 1% FBS. After 48 hr of
incubation, the cells were harvested by centrifugation at 1000 rpm
for 5 min. The cell pellets were washed twice with PBS followed
by fixation with ice-cold 70% ethanol and storage at 220uC
overnight. After centrifugation, the pellets were washed with
cold PBS, suspended in 500 ml PBS with 50 mg/ml PI (final
concentration), 0.1 mg/ml RNase A, 0.05% Triton X-100, and
incubated at 37uC for 40 min in the dark. The cell cycle
distribution was determined on the Becton Dickinson FACSCa-
liburr. The experiment was repeated thrice under the same
conditions.
Western blot analysis
Cell extracts were prepared from control as well as cells treated
with different concentrations of THA (0, 5, 10, 20, 40 mg/ml).
Briefly, the cells were washed twice with ice-cold PBS and scraped
into 100 ml lysis buffer containing 50 mM Tris (pH 7.4), 5 mM
EDTA, 0.5% NP-40, 1 mM PMSF, 150 mM NaCl and incubated
on ice for 20 min with intermittent mixing. The extract was
centrifuged for 20 min at 4uC at 12000 rpm. Cytosolic proteins
were prepared using a nuclear/cytosol fractionation kit (Pierce,
USA). Equal amount of protein was loaded on a 10–12% SDS-
PAGE gel and transferred electrophoretically to Amersham
Hybond-P PVDF membrane in sodium phosphate buffer. The
membrane was blocked in 5% milk in PBST and incubated at
room temperature for 2–4 hr with first antibody. After three
washings with 0.1% Tween-20 in TBS, the membrane was
incubated for 2 hr at room temperature with HRP-conjugated
secondary antibody. Protein bands were visualized by the ECL
system (Amersham Biosciences, USA).
Xenograft growth assay
Pathogen-free female athymic nude mice (nu/nu, 4–6 weeks)
were purchased from Shanghai Experimental Animal Centre
(Shanghai, China). All animals were fed with commercial diet and
all animal studies were approved by the Wenzhou Medical
College, Institutional Animal Care and Use Committee (approval
ID WAC-2009003). The xenograft model was established as
reported [27]. Briefly, A2780 cells were harvested and resus-
pended in serum-free RPMI 1640 medium containing 20% (v/v)
Matrigel (BD Biosciences, USA). Aliquots of cells (5610
6 cells/
0.2 ml) were injected subcutaneously into the inguinal region of
nude mice. Mice bearing palpable tumors (,50 mg) were
randomly divided into treatment and control groups (n=5
mice/group). THA was diluted in saline and was administered
via i.p. injection at doses of 25 and 50 mg/kg (inject once every
other day for 3 weeks). The control group received saline only.
The tumor growth and body weight of the mice were monitored
every other day. Tumor sizes were determined using calliper
measurement and tumor volumes (mm
3) were calculated using the
standard formula: length6width6height60.5326. Tumors were
harvested 3 weeks after treatment and individually weighed.
Statistical analysis
All data represent three independent experiments and are
expressed as the mean 6 SD unless otherwise indicated. Statistical
comparisons were made by two-tailed Student’s t-test. Significance
was considered as P,0.05.
Results
Isolation of cytotoxic compounds from Sinojackia
sarcocarpa
A two-step extraction procedure was first used to obtain an
extract enriched in alkaloids and flavanoids. This extract was then
fractionated by column chromatography into 20 fractions. The
purification process is illustrated in Figure S1. Individual fractions
Table 1. Growth inhibitory activity of the THA compound on
different cancer cell lines.
Cell lines Inhibitory concentration (mg/ml)
IC20 IC50 IC80
QSG7701 67.5 .100 .100
HepG2 14.2 29.7 52.0
IOSE144 60.0 .100 .100
A2780 11.2 24.3 34.8
A549 12.0 25.0 72.0
H1299 20.0 50.0 76.5
AGS 20.1 28.6 37.8
Eca109 6.3 26.0 36.0
CaEs17 15.2 27.0 38.7
MCF-7 37.5 55.0 72.0
MB-MDA-231 44.0 59.2 75.0
PC3 13.8 29.5 37.0
SHG-44 6.0 31.0 59.0
U251 20.3 33.7 63.6
HCT116 7.2 19.5 34.5
ARO 21.6 25.0 29.5
FRO 23.9 29.6 36.4
IC20,I C 50,a n dI C 80 were the concentrations of drug that inhibit growth by 20%,
50%, and 80%, respectively, relative to the control.
doi:10.1371/journal.pone.0021130.t001
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counterparts. (A) Ovary cancer cell A2780 and ovary epithelial cell IOSE144. (B) Hepatocelluar carcinoma cell HepG2 and normal liver cell QSG7701.
(C) The photos of clonogenic growth assay. Note the trend of the pronounced increase in growth suppression in the two cancer cell lines as the
concentration of THA increases (from left to right). Cells were exposed to various concentrations of THA for seven days followed by clonogenic assay.
All assays were done in triplicate (*, P,0.05; **, P,0.01; ***, P,0.001 versus noncancerous counterparts).
doi:10.1371/journal.pone.0021130.g002
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their cytotoxic effect on the colon cancer cell line HCT116. The
results from preliminary experiments showed that Fraction 6
exhibited the most profound cytotoxic effect on HCT116 cells.
Thus, Fraction 6 was further purified by HSCCC, resulting in a
total of 460 mg dried powder (from a 10 kg starting raw material).
HPLC analysis revealed that this powder contained primarily a
single compound with 97.97% purity (Fig. 1A). The identity of the
major constituent of the powder was then determined by a series of
analyses including IR absorptions,
1H NMR spectrum,
13C NMR
spectra analysis. The data from these analyses in aggregate
indicated that the compound was 2a,3 a,1 9 b,2 3 b-tetrahydrox-
yurs-12-en-28-oic acid (THA) (Fig. 1B) and that it has a molecular
formula of C30H48O6 and molecular weight of 504.35. To our
knowledge, this is a novel triterpenoid that has not been reported
in the literature previously.
THA inhibits cancer cell growth in vitro
A preliminary study indicated that THA did not react with the
MTT assay reagents in the absence of cells (Fig. S2).Therefore,
MTT assay was used to assess the anti-proliferation activity of this
compound. Fifteen cell lines representing ten types of human
malignancies (liver, ovary, lung, gastric, esophageal, breast,
prostate, gliomas, colon and thyroid) were cultured with THA at
concentrations in the range of 2.5,160 mg/ml for 72 hr, and a
strong reduction in cell viability was observed in a dose-dependent
manner. The concentrations that reduced growth by 20% (IC20),
50% (IC50), and 80% (IC80) are summarized in Table 1. An
important attribute of an effective anticancer drug is cancer
selectivity in its cytotoxic effect. Thus, having succeeded in
purifying a cytotoxic triterpoid from Sinojackia sarcocarpa, we asked
whether it exhibited any cancer selectivity in cell killing. First, we
compared the cytotoxic effect of this agent on two different pairs of
noncancerous-cancerous cell lines: 1) the noncancerous QSG7701
hepatocyte line and the HepG2 hepatocellular carcinoma line; 2)
the noncancerous IOSE144 ovarian epithelial line and the A2780
ovarian cancer line, respectively. The results of the initial MTT
assay experiments showed that in both cases, THA was
significantly more toxic to the cancerous cell lines than to their
noncancerous counterparts (Table 1). Clonogenic survival exper-
iments also demonstrated that THA is much more potent in
inhibiting the clonogenic survival ability of the cancer cells than
their noncancerous counterparts (Fig. 2A, 2B, 2C). These results,
therefore, suggest that THA exhibits a certain level of cancer
selectivity in terms of its cytotoxic effect under our in vitro tissue
culture condition.
THA possesses antitumor activity in vivo
The selective killing property of THA suggests that it could have
antitumor activity, i.e. suppressing the growth of tumors without
Figure 3. THA significantly inhibits ovary tumor growth in A2780 xenograft tumor model. (A) Time course of tumor growth at the
indicated THA concentrations in mice bearing A2780 tumor. (B) The corresponding body weight changes during the THA treatments. (C) The tumor
weights measured at autopsy after three weeks of THA treatment. (D) The photo of the autopsied tumors after three weeks of THA treatment
(*, P,0.05; **, P,0.01; ***, P,0.001 versus saline control).
doi:10.1371/journal.pone.0021130.g003
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21130Figure 4. THA induces dose-dependent apoptosis in human ovarian and hepatocelluar carcinoma cells. (A) Cell apoptosis analyzed with
Annexin V-FITC kit, A2780 and HepG2 cells were treated with DMSO or the indicated concentration of THA for 48 hr. (B) Apoptosis index of A2780
and HepG2 cells. Data are representative of the values from three independent experiments. Cells positive for early apoptosis and for late apoptosis
were combined, and the percentage of cellular apoptosis in control cells was regarded as 100%. (C) Comparison of the cell apoptosis induced by THA
in the cancerous A2780, HepG2 cell and noncancerous cells IOSE144 and QSG7701. Cells were treated with 30 mg/ml THA for 48 hr. (D) z-VAD-fmk
partially prevented the THA induced apoptosis in A2780 and HepG2 cells. Cells were treated with 80 mM z-VAD-fmk for 1 hr before adding
THA(40 mg/ml) for another 48 hr. (E) Dose-dependent effects of THA on DNA fragmentation in A2780 and HepG2 cells visualized by gel
electrophoresis. (*, P,0.05; **, P,0.01; ***, P,0.001 versus the control, respectively).
doi:10.1371/journal.pone.0021130.g004
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important issue, we assessed the potential antitumor activity of
THA. A preliminary study indicated that a three-week course of
daily i.p. injection of THA at concentrations as high as 50 mg/kg
body weight did not cause any obvious adverse effects on either the
daily food intake and body weight of mice (data not shown),
suggesting that low doses of THA (50 mg/kg body weight or
below) are well tolerated in mice. We then asked whether such a
‘‘non-toxic’’ doses of THA could have any antitumor activity in
vivo using an A2780 xenograft tumor model. THA was
administered via i.p. injection every other day for 3 weeks to
mice in the treatment groups. Therapeutic effects were evaluated
by examining tumor size and tumor weight. Consistent with the in
vitro findings, THA showed a dose-dependent inhibitory effect on
tumor growth (Fig. 3A). THA (at doses of 25 and 50 mg/kg)
resulted in 39% (P,0.01) and 61% (P,0.001) tumor growth
inhibition (compared to control mice treated with saline) in the
A2780 xenograft tumor model (Fig. 3C, 3D). At this dose range,
the agent did not cause a significant impact on the body weight or
any other vital signs of the animals (Fig. 3B). Thus, within the
‘‘non-toxic’’ range, THA exhibited a significant antitumor activity
to xenograft tumors derived from the A2780 ovarian cancer cell
line.
THA induces cell apoptosis
Previously, it has been reported that some triterpenoids could
induce apoptosis in cultured human cancer cells [28,29]. Thus, we
also examined whether THA could induce apoptosis in cancer
cells. After treating the A2780 and HepG2 cells with different
doses of THA, the percent of apoptotic cells was assessed by
Annexin V-FITC and propidium iodide staining, followed by flow
cytometric analysis. Exposure of A2780 and HepG2 cells to THA
for 48 hr resulted in a significant dose-dependent increase in
apoptotic cells (Fig. 4A). At 40 mg/ml concentration, there was
,10.6-fold (p,0.001) increase in the population of A2780 cells
undergoing apoptosis compared to the untreated control cells
(DMSO). Similar apoptosis index patterns were obtained when the
HepG2 were exposed to THA (Fig. 4A, 4B). Ovary epithelial cell
IOSE144 and normal liver cell QSG7701 were resistant to THA,
under 30 mg/ml exposure, the total apoptotic cells were
significantly lower when compared to the A2780 and HepG2
cells (Fig. 4C). The THA induced cell apoptosis can partially be
Figure 5. THA induces G2/M cell cycle arrest in A2780 and HepG2 cells. A2780 and HepG2 cells were treated with 0,40 mg/ml THA for 48 hr
and the cell cycle distribution was analyzed by the Becton Dickinson FACSCaliburr. (A) Histograms of the cell cycle distribution. (B, C) The percentage
of cells in different phases. The results are the mean data from triplicate repeats under the same conditions (*, P,0.05; **, P,0.01 versus the control).
doi:10.1371/journal.pone.0021130.g005
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confirm that the cancer cell death was caused by apoptosis, we also
performed a DNA fragmentation assay and found that THA dose
dependently increased apoptotic DNA fragmentation in A2780
and HepG2 cells 48 hr after THA treatment (Fig. 4E). These data
showed that THA is also a potent inducer for apoptosis and it
exerts its growth inhibition by inducing apoptosis.
THA induces a G2/M cell cycle arrest
THA is structural similar to ursolic acid, a triterpenoid that also
exhibits a potent anti-proliferative effect in human cancer cells.
Previous, it has been shown that ursolic acid treatment caused a
G1 arrest [30]. Thus, we also examined the effect of THA
treatment on cell cycle progression. We found that THA induced a
dose-dependent cell cycle arrest in the G2/M phase of A2780 and
HepG2 cells (Fig. 5A). Treatment of A2780 cells with THA at the
concentration of 40 mg/ml for 48 hr resulted in significant cell
cycle arrest at G2/M phase which was accompanied by a decrease
in G0/G1 phase cells. Also, a slight increase in the S phase
population was observed after each THA treatment. The amount
of G2/M-phase cells was tripled in the treated A2780 cells,
compared to the controls, whereas G0/G1-phase cells were re-
duced by nearly 56% (p,0.01; Fig. 5B). A similar result was also
observed in HepG2 cells (Fig. 5C). Thus, THA and ursolic acid,
despite their structural similarity, have different effects on cell cycle
progression, suggesting that they exert their growth inhibitions via
different mechanisms.
THA alters the expression of apoptosis-related proteins
To examine the possible pathway of anti-proliferative, pro-
apoptotic, and cell cycle arrest upon treatment with THA, we
compared the expression of various proteins involved in these
processes by Western blot. Consistent with its effect on apoptosis,
THA induced changes in the expression of apoptosis related
proteins in A2780 and HepG2 cells. The expression of procaspase-
3, -8, -9, and c-Myc were clearly decreased in a dose-dependent
Figure 6. THA changes the expression of proteins related to apoptosis and cell cycle arrest. A2780 and HepG2 cells were exposed to
various concentrations (0, 5, 10, 20 and 40 mg/ml) of THA for 48 hr, and protein levels were determined by Western blot. (A) The expression changes
of caspases, PARP, c-Myc and cell cycle related proteins. (B) The release of cytoplasmic Cytochrome c from mitochondrion induced by THA treatment.
(C) The expression of the apoptosis related proteins Bax and Bcl-2.
doi:10.1371/journal.pone.0021130.g006
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was no change for the Fas expression (Fig. 6A). Moreover, the
PARP cleavage was induced, where the 116 kd protein was
cleaved to an 89 kd catalytic fragment (Fig. 6A). THA also
induced changes in the expression of cell cycle regulatory proteins,
and the expression level of Cdc2 were decreased clearly (Fig. 6A).
In addition, cytosolic release of Cytochrome c from mitochondrion
was detected in both cells (Fig. 6B). Moreover, A2780 and HepG2
cells exposed to THA showed a dose-dependent reduction in the
level of Bcl-2 protein, with a concomitant increase in the level of
Bax and the Bax/Bcl-2 ratio, compared with the control cells
(Fig. 6C).
Discussion
Triterpenoids represent an emerging class of promising
anticancer agents [7,9]. Here we have reported the isolation
of 2a,3 a,1 9 b,2 3 b-tetrahydroxyurs-12-en-28-oic acid (THA),
a novel triterpenoid compound from the leaves of Sinojackia
sarcocarpa. We showed that this compound exhibited a high degree
of cancer-selectivity in its cytotoxic effect in both in vitro and in vivo
settings. Together, our data have strongly demonstrated that THA
represents an attractive candidate as an anticancer agent. It is a
new addition to the class of triterpenoid compounds which possess
anti-proliferative/anticancer activities.
To elucidate the anti-cancer mechanism of THA, we investi-
gated cell apoptosis, the cell cycle and the expression of the
proteins following THA treatments. Our data showed that THA
treatment induced strong cell apoptosis in both A2780 and HepG2
cells (Fig. 4). Apoptosis is an active physiologic process of cellular
self-destruction, with specific biochemical changes in the nucleus
and cytoplasm via either the intrinsic (mitochondrial) or extrinsic
pathways [31,32]. The intrinsic pathway is characterized by the
release of Cytochrome c from the mitochondria to the cytoplasm
and activation of the caspase-dependent and -independent
pathway [33]. In this study, we found that THA treatment
induced the release of Cytochrome c from the mitochondria in a
dose-dependt manner, resulting in the activation of procaspase-9
and procaspase-3. Moreover, these changes are associated with a
significant increase in the cleavage and activation of PARP, a
target protein of caspase-3 (Fig. 6A, 6B). Together, these data
indicate the involvement of intrinsic pathway in THA-induced
apoptosis. THA is structurally related to ursolic acid, a major
member of the triterpenoid family with anti-proliferative/antican-
cer activities that have already been reported [34,35]. Interest-
ingly, both agents significantly suppress the expression of Bcl-2 and
increase the expression of Bax. Bcl-2 and Bax are important
members linked to mitochondrial control during apoptosis: Bax, a
pro-apoptotic member, favors the leakage of apoptogenic factors
from mitochondria, and Bcl-2, an anti-apoptotic member,
negatively regulates this leakage [36,37]. The changes in the
levels of Bcl-2 and Bax expression are consistent with those of
caspases and Cytochrome c, supporting the conclusion that the
intrinsic pathway is the major mechanism of apoptosis following
THA exposure. However, we have noted that despite their
structural similarity, THA and ursolic acid appears to have
different effects on cell cycle progression. For examples, THA
causes a G2/M arrest, while ursolic acid induces primarily a G1
arrest [30]. This difference strongly suggests that these two drugs
may exert their growth suppression on human cancer cells via
distinctive mechanisms. Intriguingly, we have also noticed a slight
increase in the S phase population following THA treatments,
indicating that THA also has an effect on S phase progression.
This has also raised the possibility that the G2/M arrest and
growth suppressive effect of THA could have originated, at least
partly, from its effect on S phase progression. Future experiments
will shed new lights on the underlying mechanisms or potential
targets of these various types of triterpenoids, and will hopefully
promote the development of these agents as anticancer drugs.
Supporting Information
Figure S1 The isolation process of 2a,3 a,1 9 b,2 3 b-
tetrahydroxyurs-12-en-28-oic acid (THA) from the leaves
of Sinojackia sarcocarpa.
(TIF)
Figure S2 THA did not react with the MTT assay
reagents. Various concentrations of THA were added in the
96-well plate in the absence of cells, MTT assay was performed
and the absorbance of 550 nm was measured.
(TIF)
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